

Board restructure supports transition to commercial medical technology firm

- Dr Martin Rogers to join board as Deputy Chair;
- Mr Rod Tomlinson to step down as Chair and non-executive Director to become executive chair of Scientific Advisory Committee, Mr Fabio Pannuti to assume role as Executive Chairman.

Melbourne, Monday 3 September 2012. Consegna Group Limited (**ASX:CGP**) today announced that effective immediately Mr Martin Rogers, the former CEO and current non-executive Director of Prima BioMed Limited, will join the board as a non-executive Director and Deputy Chairman of the Company.

Mr Rogers has Chemical Engineering and Science degrees and has a successful track record in incubating companies and publicly listed organisations. He has experience in all aspects of financial, strategic and operational management and has raised over \$100m cash equity. Mr Rogers has been both an investor and senior executive in a privately funded advisory business in the science and biotechnology sectors, where he was instrumental in significantly increasing the value of those investments.

Mr Rogers has also held roles with the management committee of the National Breast Cancer Foundation and Trustee of the University of Sydney Physics Foundation and International Science School.

Mr Rod Tomlinson, Chairman of Consegna will step down from this role and as a non-executive director and focus solely on his role as Chair of the Scientific Advisory Committee.

Mr Tomlinson said: *“My first love is working closely with the scientific teams to develop new and exciting medical solutions. As the company is now well positioned for growth, this role allows me to focus my attention on the considerable capacity we have within the company and to further identify, package and exploit life science technologies.”*

Consegna CEO Mr Fabio Pannuti added: *“I would like to express the Board’s appreciation to Rod as our Chairman post the acquisition of BreatheAssist and Vibrovein and through the Linguet and Aspen transactions. He has overseen a highly successful period and we are fortunate to retain Rod’s expertise as chair of the Scientific Advisory Committee where we will be able to access his significant experience in commercialising life science assets.”*

Coinciding with Mr Tomlinson’s resignation, Mr Fabio Pannuti will assume the role of Executive Chairman. This structural change will provide greater flexibility to build the executive management team as the company continues to transition from a company with IP to a commercial medical technology firm with income producing assets.



CONSEGNA
DELIVERING INNOVATION

‘THE GRAIN STORE’
7/21 NORTHUMBERLAND ST
COLLINGWOOD
MELBOURNE, VIC 3002

TEL. 03 9417 5001
FAX. 03 8080 0796
INFO@CONSEGNA.COM

ACN. 107 903 159

In July 2012 Consegna sold its Linguet technology asset, which was purchased in July 2011, to ASX listed Imugene (ASX:IMU) for 100m shares with a current market value of \$1.3m. Imugene will continue to commercialise the Linguet technology in the nutraceutical and pharmaceutical space. , Consegna is also currently in the final stages of due diligence with US based Triple AAA for the worldwide licensing of the BreatheAssist asset.

Mr Pannuti concluded: *“We are delivering on our objectives with two strong deals after 18 months of operation. The strength of our team and our strategy is delivering returns. The purchase, package, profit strategy is delivering the sale of our technologies at considerable premiums. We are extremely pleased to add the extensive skills and experience of Martin Rogers to the board as we transition to the next stage of Consegna’s development.”*

ENDS

For further information, please contact Consegna Group Limited on (03) 9417 5001.

About Consegna Group Limited

Consegna Group Limited’s purpose is to identify, acquire and commercialise late stage therapeutic delivery technologies. The Company targets high value markets and indications using an acquisition strategy driven by strategic value creation, patent protection and realisation criteria. The Company employs a low fixed overhead model with a panel of successful, best in field regulatory, intellectual property and scientific advisors.